Both companies to be acquired serve biopharmas and academic institutions by offering culture media for biopharmaceutical production, in vitro fertilization, and cell therapy
Biovest and Ordway Research Institute to Evaluate Firm’s Technology for Producing Virus-Fighting Products
Studies will establish prototype for large-scale production of viruses using Biovest's hollow fiber bioreactor systems.
Domain Therapeutics inked a licensing and partnership agreement on G-protein coupled receptors (GPCR) biosensor technology with Université de Montréal (UdeM) and its commercialization unit, with the Institute for Research in Immunology and Cancer–Commercialization of...
EMD Millipore and Samsung BioLogics signed a Memorandum of Understanding (MOU) for a strategic alliance to encompass a long-term supply agreement.
Synthetic biologists establish a DNA-encoded and readily engineered bacterial platform for borylation that outpaces conventional chemical methods
Enhanced cleanroom is key feature. Gore PharmBIO Products opened a new manufacturing facility, which doubles its capacity. Located in Elkton, MD, the site will house a cleanroom that is designed to be more efficient and...
Firm claims Genetic Elements platform can reduce development time to five weeks.
EMD Millipore, Centre for Commercialization of Regen Med to Optimize Large-Scale Stem Cell Cultivation
Monitoring and control methodology will be developed for EMD’s Mobius CellReady bioreactor.
Integrity® Xpansion™ will be integrated into Orgenesis' therapy, which converts liver cells to insulin-producing cells.
Please wait while you are redirected to the right page...